Taysha Gene Therapies (TSHA) PT Raised to $43 at Morgan Stanley
Tweet
Share
E-mailGet Alerts TSHA Hot Sheet
Price: $5.81 -3.01%
Rating Summary:
17 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 11
Rating Summary:
17 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 11
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison raised the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $43.00 (from $30.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Zedcor Inc (ZDC:CN) PT Raised to Cdn$7.75 at Desjardins
- Lithium Ionic Corp (LTH:CN) PT Lowered to Cdn$2.50 at Desjardins
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
